OncoSil Medical Full Year 2023 Earnings: AU$0.01 loss per share (vs AU$0.013 loss in FY 2022)
OncoSil Medical (ASX:OSL) Full Year 2023 Results
Key Financial Results
Net loss: AU$11.3m (loss widened by 5.7% from FY 2022).
AU$0.01 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
OncoSil Medical shares are up 10.0% from a week ago.
Risk Analysis
Before you take the next step you should know about the 6 warning signs for OncoSil Medical (4 are potentially serious!) that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
